Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Defence Therapeutics

Main (gene editing) focus: Novel methods for delivery of gene-editing systems

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:DTCFF)

Location: Vancouver, British Columbia, Canada


Defence Therapeutics develops a proprietary platform called ACCUMTM, which enables precision delivery of vaccine antigens or drugs to target cells. The company recently announced strong in vitro results for the delivery of the CRISPR-Cas9 system using ACCUMTM technology. The company now seeks collaborations in the gene-editing space.


HashtagDefence Therapeutics

Company: Defence Therapeutics
Search CRISPR Medicine